Skip to content Skip to navigation

Intratympanic gentamicin for the treatment of Meniere's disease and other forms of peripheral vertigo.

TitleIntratympanic gentamicin for the treatment of Meniere's disease and other forms of peripheral vertigo.
Publication TypeJournal Article
Year of Publication2004
AuthorsCarey J
JournalOtolaryngol Clin North Am
Volume37
Issue5
Pagination1075-90
Date Published2004 Oct
ISSN0030-6665
KeywordsAdministration, Topical, Anti-Bacterial Agents, Gentamicins, Humans, Meniere Disease, Round Window, Ear, Tympanic Membrane, Vertigo
Abstract

<p>Titration therapy with intratympanic gentamicin offers class A or B control of vertigo in 87% (range, 75%-100%) of patients with unilateral Ménière's disease. The risk of additional hearing loss is about 21% (range,0-37%). Vertigo may recur, however, in nearly one third of patients over time. These recurrences can also be treated by intratympanic gentamicin with a similar risk of hearing loss. The salient effect of intratympanic gentamicin is probably the reduction of vestibular function through damage to hair cells, but a complete ablation of function does not seem to be necessary for vertigo control.</p>

DOI10.1016/j.otc.2004.06.002
Alternate JournalOtolaryngol. Clin. North Am.
Citation KeyCK42
PubMed ID15474112